개 아토피 피부염 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 견종별, 투여 방법별, 적응증별, 유통 채널별, 지역별 및 부문 동향(2025-2030년)

Canine Atopic Dermatitis Market Size, Share & Trends Analysis Report By Product (Glucocorticoids, Antihistamines), By Type, By Dog Breed, By Mode Of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,641,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,094,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,998,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

개 아토피 피부염 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 개 아토피 피부염 시장 규모는 2030년까지 87억 8,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 10.6%의 CAGR로 확대될 것으로 예측됩니다.

개 아토피 피부염의 유병률 증가와 수의학 발전이 시장 성장의 원동력이 되고 있습니다. 반려견의 피부 알레르기 사례의 증가는 효과적인 치료법에 대한 수요 증가로 이어지고 있습니다. 단클론항체 및 면역억제제 개선과 같은 기술 혁신은 치료 효과를 향상시켜 시장 확대에 박차를 가하고 있습니다. 연구 개발 노력은 새로운 치료법을 지속적으로 개발하여 치료 효과와 접근성을 향상시키고 있습니다.

개 아토피 피부염 시장은 반려동물 사육 증가와 보호자의 인식 개선에 힘입어 성장하고 있습니다. 반려견을 키우는 가정이 증가함에 따라 피부과 치료에 대한 수요가 증가하고 있습니다. 반려동물 보호자들이 적극적으로 치료를 받으려는 경향이 높아지면서 전문적인 치료법 채택이 증가하고 있습니다. 반려동물 의료비 지출 증가와 진단 능력의 향상도 시장 성장에 기여하고 있습니다.

반려동물 웰빙에 대한 관심 증가와 수의학 의료 인프라 확대가 시장 성장을 촉진할 것으로 예상됩니다. 강화된 수의학 시설과 피부과 전문 클리닉은 고급 치료에 대한 접근성을 향상시킬 것입니다. 반려동물 헬스케어에 대한 투자 증가는 시장 확대를 더욱 촉진할 것이며, 제약사들은 수요 증가에 대응하기 위해 혁신적인 솔루션을 개발하고 있습니다.

개 아토피 피부염 시장 보고서 하이라이트

• 제품별로는 글루코코르티코이드 분야가 2024년 38.3%의 최대 매출 점유율로 시장을 주도하고 있습니다.
• MAbs 부문은 알레르기 반응을 관리하기 위한 표적화된 접근 방식으로 인해 예측 기간 동안 가장 빠르게 성장하는 부문이 될 것으로 예상됩니다.
• 유형별로는 처방약 부문이 2024년 가장 큰 점유율을 차지하며 시장을 장악했습니다.
• OTC 부문은 접근성이 좋고 저렴한 치료제에 대한 선호도가 높아짐에 따라 2025-2030년 사이 가장 빠르게 성장할 것으로 예상됩니다.
• 북미는 2024년 40.4%로 가장 큰 매출 점유율을 차지했으며, 높은 수의학 의료 인프라와 높은 반려동물 양육률에 힘입어 성장세를 이어갈 것으로 보입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장개 아토피 피부염 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 개 아토피 피부염 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장개 아토피 피부염 시장 : 제품 추정·동향 분석

• 제품 부문 대시보드
• 제품 변동 분석
• 세계의 개 아토피 피부염 시장 규모와 동향 분석(제품별, 2018-2030년)
• 글루코코르티코이드
• 항히스타민제
• 면역억제제
• 단클론항체
• 기타

제5장개 아토피 피부염 시장 : 유형 추정·동향 분석

• 유형 부문 대시보드
• 유형 변동 분석
• 세계의 개 아토피 피부염 시장 규모와 동향 분석(유형별, 2018-2030년)
• 처방전
• 시판약

제6장개 아토피 피부염 시장 : 견종 추정·동향 분석

• 견종 부문 대시보드
• 견종 변동 분석
• 세계의 개 아토피 피부염 시장 규모와 동향 분석(견종별, 2018-2030년)
• 저먼 셰퍼드
• 테리어
• 리트리버
• 기타

제7장개 아토피 피부염 시장 : 투여 방법 추정·동향 분석

• 관리 모드 부문 대시보드
• 투여 방법 변동 분석
• 개 아토피 피부염 세계 시장 규모와 동향 분석(투여 방법별, 2018-2030년)
• 경구
• 국소
• 주사제

제8장개 아토피 피부염 시장 : 적응증 추정·동향 분석

• 적응증 부문 대시보드
• 적응증 변동 분석
• 개 아토피 피부염 세계 시장 규모와 동향 분석(적응증별, 2018-2030년)
• 외부기생충
• 식품 알레르기
• 알레르기성 피부 감염증
• 기타

제9장개 아토피 피부염 시장 : 유통 채널 추정·동향 분석

• 유통 채널 부문 대시보드
• 유통 채널 변동 분석
• 세계의 개 아토피 피부염 시장 규모와 동향 분석(유통 채널별, 2018-2030년)
• 동물 병원/클리닉
• 소매
• E-Commerce

제10장개 아토피 피부염 시장 : 지역 추정·동향 분석

• 지역 시장 대시보드
• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별개 아토피 피부염 시장 : 주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제11장 경쟁 구도

• 주요 시장 진입 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • Key Company Heat Map Analysis, 2024
• 기업 개요
  • Zoetis Services LLC
  • Merck & Co., Inc.
  • Elanco
  • Boehringer Ingelheim International GmbH
  • Virbac
  • Vetoquinol
  • Dechra
  • Biofelix Pharma Group
  • TORAY INDUSTRIES, INC.
  • Bioiberica SAU
  • Ceva
  • Bimeda, Inc.

ksm

영문 목차

영문목차

Canine Atopic Dermatitis Market Growth & Trends:

The global canine atopic dermatitis market size is anticipated to reach USD 8.78 billion by 2030 and expand at a CAGR of 10.6% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of canine atopic dermatitis and advancements in veterinary medicine are driving market growth. Increasing cases of skin allergies in dogs have led to higher demand for effective treatments. Innovations such as monoclonal antibodies and improved immunosuppressants enhance therapeutic outcomes, fueling market expansion. Research and development efforts continue to drive novel therapies, improving treatment efficacy and accessibility.

Growing pet ownership and increased awareness among pet owners propel the canine atopic dermatitis market. As more households adopt dogs, the demand for dermatological care rises. Pet owners are becoming more proactive in seeking treatment, leading to higher adoption of specialized therapies. The rise in pet healthcare spending and improved diagnostic capabilities further contribute to market growth.

The increasing focus on companion animal wellness and expanding veterinary healthcare infrastructure are expected to drive market growth. Enhanced veterinary facilities and specialized dermatology clinics improve access to advanced treatments. Rising investments in pet healthcare further support the market expansion, with pharmaceutical companies developing innovative solutions to meet growing demand.

Canine Atopic Dermatitis Market Report Highlights:

• By product, the glucocorticoids segment led the market with the largest revenue share of 38.3% in 2024, fueled by its widespread use in managing inflammation and allergic reactions in dogs.
• The MAbs segment is set to be the fastest-growing segment during the forecast period,attributed to its targeted approach to managing allergic reactions.
• By type, the prescription segment dominated the market with the largest share in 2024, driven by the growing reliance on veterinarian-recommended treatments.
• The OTC segment is set to witness the fastest growth from 2025 to 2030 due to increasing preference for accessible and affordable treatments.
• North America accounted for the largest revenue share of 40.4% in 2024, propelled by its advanced veterinary healthcare infrastructure and high pet ownership rates.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Dog Breed
  • 1.2.4. Mode of Administration
  • 1.2.5. Indication
  • 1.2.6. Distribution Channel
  • 1.2.7. Regional Scope
  • 1.2.8. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Type Outlook
  • 2.2.3. Dog Breed Outlook
  • 2.2.4. Mode of Administration Outlook
  • 2.2.5. Indication Outlook
  • 2.2.6. Distribution Channel Outlook
  • 2.2.7. Regional Outlook
• 2.3. Competitive Scenario

Chapter 3. Canine Atopic Dermatitis Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Canine Atopic Dermatitis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Canine Atopic Dermatitis Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Canine Atopic Dermatitis Market: Product Movement Analysis
• 4.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
• 4.4. Glucocorticoids
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Antihistamines
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Immunosuppressants
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.7. MAbs
  • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Canine Atopic Dermatitis Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. Canine Atopic Dermatitis Market: Type Movement Analysis
• 5.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
• 5.4. Prescription
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. OTC
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Canine Atopic Dermatitis Market: Dog Breed Estimates & Trend Analysis

• 6.1. Dog Breed Segment Dashboard
• 6.2. Canine Atopic Dermatitis Market: Dog Breed Movement Analysis
• 6.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Dog Breed, 2018 to 2030 (USD Million)
• 6.4. German Shepherd
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Terriers
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Retrievers
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Canine Atopic Dermatitis Market: Mode of Administration Estimates & Trend Analysis

• 7.1. Mode of Administration Segment Dashboard
• 7.2. Canine Atopic Dermatitis Market: Mode of Administration Movement Analysis
• 7.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Mode of Administration, 2018 to 2030 (USD Million)
• 7.4. Oral
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Topical
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Injectable
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Canine Atopic Dermatitis Market: Indication Estimates & Trend Analysis

• 8.1. Indication Segment Dashboard
• 8.2. Canine Atopic Dermatitis Market: Indication Movement Analysis
• 8.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Indication, 2018 to 2030 (USD Million)
• 8.4. Ectoparasites
  • 8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.5. Food Allergy
  • 8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.6. Allergic Skin Infections
  • 8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 9. Canine Atopic Dermatitis Market: Distribution Channel Estimates & Trend Analysis

• 9.1. Distribution Channel Segment Dashboard
• 9.2. Canine Atopic Dermatitis Market: Distribution Channel Movement Analysis
• 9.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
• 9.4. Veterinary Hospitals/Clinics
  • 9.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 9.5. Retail
  • 9.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 9.6. E-commerce
  • 9.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 10. Canine Atopic Dermatitis Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Dashboard
• 10.2. Regional Market Share Analysis, 2024 & 2030
• 10.3. Canine Atopic Dermatitis Market by Region: Key Takeaways
• 10.4. North America
  • 10.4.1. U.S.
    • 10.4.1.1. Key Country Dynamics
    • 10.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 10.4.1.3. Competitive Scenario
    • 10.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.4.2. Canada
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.4.2.3. Competitive Scenario
    • 10.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.4.3. Mexico
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.4.3.3. Competitive Scenario
    • 10.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.5. Europe
  • 10.5.1. U.K.
    • 10.5.1.1. Key Country Dynamics
    • 10.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.1.3. Competitive Scenario
    • 10.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.2. Germany
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.2.3. Competitive Scenario
    • 10.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.3. France
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.3.3. Competitive Scenario
    • 10.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.4. Italy
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.4.3. Competitive Scenario
    • 10.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.5. Spain
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.5.3. Competitive Scenario
    • 10.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.6. Denmark
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.6.3. Competitive Scenario
    • 10.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.7. Sweden
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.7.3. Competitive Scenario
    • 10.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.8. Norway
    • 10.5.8.1. Key Country Dynamics
    • 10.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.8.3. Competitive Scenario
    • 10.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.6. Asia Pacific
  • 10.6.1. Japan
    • 10.6.1.1. Key Country Dynamics
    • 10.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.1.3. Competitive Scenario
    • 10.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.2. China
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.2.3. Competitive Scenario
    • 10.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.3. India
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.3.3. Competitive Scenario
    • 10.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.4. Australia
    • 10.6.4.1. Key Country Dynamics
    • 10.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.4.3. Competitive Scenario
    • 10.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.5. South Korea
    • 10.6.5.1. Key Country Dynamics
    • 10.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.5.3. Competitive Scenario
    • 10.6.5.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.6. Thailand
    • 10.6.6.1. Key Country Dynamics
    • 10.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.6.3. Competitive Scenario
    • 10.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.7. Latin America
  • 10.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.7.2. Brazil
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.7.2.3. Competitive Scenario
    • 10.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.7.3. Argentina
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.7.3.3. Competitive Scenario
    • 10.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.8. Middle East and Africa
  • 10.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.2. South Africa
    • 10.8.2.1. Key Country Dynamics
    • 10.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.2.3. Competitive Scenario
    • 10.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.3. Saudi Arabia
    • 10.8.3.1. Key Country Dynamics
    • 10.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.3.3. Competitive Scenario
    • 10.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.4. UAE
    • 10.8.4.1. Key Country Dynamics
    • 10.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.4.3. Competitive Scenario
    • 10.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.5. Kuwait
    • 10.8.5.1. Key Country Dynamics
    • 10.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.5.3. Competitive Scenario
    • 10.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Recent Developments & Impact Analysis, By Key Market Participants
• 11.2. Company/ Competition Categorization
• 11.3. Vendor Landscape
  • 11.3.1. Key Company Heat Map Analysis, 2024
• 11.4. Company Profiles
  • 11.4.1. Zoetis Services LLC
    • 11.4.1.1. Company Overview
    • 11.4.1.2. Financial Performance
    • 11.4.1.3. Product Benchmarking
    • 11.4.1.4. Strategic Initiatives
  • 11.4.2. Merck & Co., Inc.
    • 11.4.2.1. Company Overview
    • 11.4.2.2. Financial Performance
    • 11.4.2.3. Product Benchmarking
    • 11.4.2.4. Strategic Initiatives
  • 11.4.3. Elanco
    • 11.4.3.1. Company Overview
    • 11.4.3.2. Financial Performance
    • 11.4.3.3. Product Benchmarking
    • 11.4.3.4. Strategic Initiatives
  • 11.4.4. Boehringer Ingelheim International GmbH
    • 11.4.4.1. Company Overview
    • 11.4.4.2. Financial Performance
    • 11.4.4.3. Product Benchmarking
    • 11.4.4.4. Strategic Initiatives
  • 11.4.5. Virbac
    • 11.4.5.1. Company Overview
    • 11.4.5.2. Financial Performance
    • 11.4.5.3. Product Benchmarking
    • 11.4.5.4. Strategic Initiatives
  • 11.4.6. Vetoquinol
    • 11.4.6.1. Company Overview
    • 11.4.6.2. Financial Performance
    • 11.4.6.3. Product Benchmarking
    • 11.4.6.4. Strategic Initiatives
  • 11.4.7. Dechra
    • 11.4.7.1. Company Overview
    • 11.4.7.2. Financial Performance
    • 11.4.7.3. Product Benchmarking
    • 11.4.7.4. Strategic Initiatives
  • 11.4.8. Biofelix Pharma Group
    • 11.4.8.1. Company Overview
    • 11.4.8.2. Financial Performance
    • 11.4.8.3. Product Benchmarking
    • 11.4.8.4. Strategic Initiatives
  • 11.4.9. TORAY INDUSTRIES, INC.
    • 11.4.9.1. Company Overview
    • 11.4.9.2. Financial Performance
    • 11.4.9.3. Product Benchmarking
    • 11.4.9.4. Strategic Initiatives
  • 11.4.10. Bioiberica S.A.U.
    • 11.4.10.1. Company Overview
    • 11.4.10.2. Financial Performance
    • 11.4.10.3. Product Benchmarking
    • 11.4.10.4. Strategic Initiatives
  • 11.4.11. Ceva
    • 11.4.11.1. Company Overview
    • 11.4.11.2. Financial Performance
    • 11.4.11.3. Product Benchmarking
    • 11.4.11.4. Strategic Initiatives
  • 11.4.12. Bimeda, Inc.
    • 11.4.12.1. Company Overview
    • 11.4.12.2. Financial Performance
    • 11.4.12.3. Product Benchmarking
    • 11.4.12.4. Strategic Initiatives

관련자료